Structure for peptidase C01.032: cathepsin L

Summary Gene structure Alignment Tree Sequences Sequence features Distribution Structure Literature Substrates Pharma

PDB	Organism	Resolution	Comment
1CJL	Homo sapiens	2.20 Å	precursor
Catalytic residues are shown in ball-and-stick representation: Cys138 (engineered to be serine) in yellow, His276 in purple and Asn300 in pink. The propeptide is shown in grey.

		Show surface

1CS8_P	Homo sapiens	1.80 Å	procathepsin L
Only the propeptide is shown.

		Show surface

TERTIARY STRUCTURE DATA
Comment	Resolution	PDB	PDBe	SCOP	CATH	PDBSum	Proteopedia	Reference
Homo sapiens
precursor	2.20 Å	1CJL	1CJL	1CJL	1CJL	1CJL	1CJL	Coulombe et al., 1996
procathepsin L	2.20 Å	1CJL	1CJL	1CJL	1CJL	1CJL	1CJL	Coulombe et al., 1996
precursor	1.80 Å	1CS8	1CS8	1CS8	1CS8	1CS8	1CS8
procathepsin L	1.80 Å	1CS8	1CS8	1CS8	1CS8	1CS8	1CS8
complex with MHC class II associated P41 II fragment	2.00 Å	1ICF	1ICF	1ICF	1ICF	1ICF	1ICF	Guncar et al., 1999
complex with propeptide-based inhibitor biphenyl-4-yl-acetaldehyde-Cys-D-Arg-Tyr-2-phenylethylamine	1.90 Å	1MHW	1MHW	1MHW	1MHW	1MHW	1MHW	Chowdhury et al., 2002
complex with chagasin	1.75 Å	2NQD	2NQD	2NQD	2NQD	2NQD	2NQD	Ljunggren et al., 2007
cathsilicatein, a chimera	1.50 Å	2VHS	2VHS	2VHS	2VHS	2VHS	2VHS	Fairhead et al., 2008
complex with a nitrile inhibitor	1.45 Å	2XU1	2XU1	2XU1	2XU1	2XU1	2XU1
complex with a nitrile inhibitor	0.90 Å	2XU3	2XU3	2XU3	2XU3	2XU3	2XU3
complex with a nitrile inhibitor	1.12 Å	2XU4	2XU4	2XU4	2XU4	2XU4	2XU4
complex with a nitrile inhibitor	1.60 Å	2XU5	2XU5	2XU5	2XU5	2XU5	2XU5
complex with a nitrile inhibitor	1.15 Å	2YJ2	2YJ2	2YJ2	2YJ2	2YJ2	2YJ2
complex with a nitrile inhibitor	1.30 Å	2YJ8	2YJ8	2YJ8	2YJ8	2YJ8	2YJ8
complex with a nitrile inhibitor	1.35 Å	2YJ9	2YJ9	2YJ9	2YJ9	2YJ9	2YJ9
complex with a nitrile inhibitor	1.40 Å	2YJB	2YJB	2YJB	2YJB	2YJB	2YJB
complex with a nitrile inhibitor	1.14 Å	2YJC	2YJC	2YJC	2YJC	2YJC	2YJC
exploring inhibitor binding at the s subsites of cathepsin l	2.20 Å	3BC3	3BC3	3BC3	3BC3	3BC3	3BC3	Chowdhury et al., 2008
complex with retro-binding inhibitor compound 4	2.50 Å	3H89	3H89	3H89	3H89	3H89	3H89
complex with retro-binding inhibitor compound 9	1.80 Å	3H8B	3H8B	3H8B	3H8B	3H8B	3H8B
complex with retro-binding inhibitor compound 14	2.50 Å	3H8C	3H8C	3H8C	3H8C	3H8C	3H8C
complex with az12878478	1.27 Å	3HHA	3HHA	3HHA	3HHA	3HHA	3HHA
cathepsin l with az13010160	2.33 Å	3HWN	3HWN	3HWN	3HWN	3HWN	3HWN
Cys25Ala mutant	2.20 Å	3IV2	3IV2	3IV2	3IV2	3IV2	3IV2
Cys25Ala mutant; complex with Gln-Leu-Ala peptide	2.50 Å	3K24	3K24	3K24	3K24	3K24	3K24
complex with dipeptidyl glyoxal and diazomethylketone inhibitors	2.20 Å	3OF8	3OF8	3OF8	3OF8	3OF8	3OF8
complex with adiazomethylketone inhibitor	1.76 Å	3OF9	3OF9	3OF9	3OF9	3OF9	3OF9
human cathepsin l apo form with zn	1.92 Å	4AXL	4AXL	4AXL	4AXL	4AXL	4AXL
triazine cathepsin inhibitor complex	2.80 Å	4AXM	4AXM	4AXM	4AXM	4AXM	4AXM
complex with (2s,4r)-4-(2-chloro-4-methoxy- benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]- pyrrolidine-2-carboxylic acid (1-cyano-cyclopropyl)-amide	1.43 Å	5F02	5F02	5F02	5F02	5F02	5F02
cleaved cathepsin L bound to the active site of cathepsin L	1.42 Å	5I4H	5I4H	5I4H	5I4H	5I4H	5I4H
complex with (2s,4r)-4-(2-chloro-4-methoxy- benzenesulfonyl)-1-[3-(5-chloro-pyridin-2-yl)-azetidine-3-carbonyl]- pyrrolidine-2-car boxylic acid (1-cyano-cyclopropyl)-amide	1.00 Å	5MAE	5MAE	5MAE	5MAE	5MAE	5MAE
complex with 4-[cyclopentyl(imidazo[1,2-a]pyridin-2- ylmethyl)amino]-6-morpholino-1,3,5-triazine-2-carbonitrile	1.00 Å	5MAJ	5MAJ	5MAJ	5MAJ	5MAJ	5MAJ
complex with 4-[1,3-benzodioxol-5-ylmethyl(2- phenoxyethyl)amino]-5-fluoropyrimidine-2-carbonitrile	1.13 Å	5MQY	5MQY	5MQY	5MQY	5MQY	5MQY
complex with (3s,14e)-19-chloro-n-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6(11),7,9, 14,18(22),19-heptaene-3-carboxamide	1.37 Å	6EZP	6EZP	6EZP	6EZP	6EZP	6EZP
complex with (3s,14e)-19-chloro-n-(1-cyanocyclopropyl)-5-oxo-17-oxa-4-azatricyclo[16.2.2.06,11]docosa-1(21),6,8,10,14, 18(22),19-heptaene-3-carboxamide	2.34 Å	6EZX	6EZX	6EZX	6EZX	6EZX	6EZX
complex with (3s,14e)-8-(azetidin-3-yl)-19-chloro-n-(1-cyanocyclopropyl)-5-oxo-12,17-dioxa-4-azatricyclo[16.2.2.06, 11]docosa-1(21),6,8,10,14,18(22),19-heptaene-3-carboxamide	2.02 Å	6F06	6F06	6F06	6F06	6F06	6F06
Mus musculus
theoretical model	0.00 Å	1MVV	1MVV	1MVV	1MVV	1MVV	1MVV